அமெரிக்கன் சமூகம் ஆஃப் கதிர்வீச்சு புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article SUNNYVALE, Calif., Jan. 19, 2021 /PRNewswire/  Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated partial breast irradiation (APBI) delivered with the TomoTherapy ® System. The study, published online in the International Journal of Radiation Oncology Biology Physics, also reported that the once-daily schedule was associated with a very low incidence of acute and late toxicities. The TomoTherapy platform, including the next-generation Radixact ® System, is the first in the world capable of helical radiation delivery. Image-guided, intensity-modulated radiation therapy (IG-IMRT) is continuously delivering from a full 360 degrees around the patient as the treatment table also moves at a deliberate pace, providing greater control of the radiation dose so it

United statesBeth kaplanFabienne hirigoyenberry lansonInternational journal of radiation oncology biology physicsAmerican society of radiation oncologyAccuray incorporatedDepartment of radiation oncologyInternational journalUgo de paulaRadiation oncologySan giovanni addolorata hospitalAmerican societyஒன்றுபட்டது மாநிலங்களில்பெத் கபிலன்சர்வதேச இதழ் ஆஃப் கதிர்வீச்சு புற்றுநோயியல் உயிரியல் இயற்பியல்அமெரிக்கன் சமூகம் ஆஃப் கதிர்வீச்சு புற்றுநோயியல்